Cardiovascular Diseases Clinical Trial
To determine whether combined therapy with the lipid lowering agents colestipol hydrochloride plus niacin would produce significant change in coronary, carotid, and femoral artery atherosclerosis and coronary bypass graft lesions as determined by angiography. Also, to determine possible correlations between lesion changes and plasma lipid and lipoprotein cholesterol levels and to explore interrelationships of atherosclerosis change in femoral, coronary, and carotid arteries.
BACKGROUND:
The Lipid Research Clinics Coronary Primary Prevention Trial and the Coronary Drug Project
had shown that morbidity and mortality from ischemic heart disease were reduced by blood
cholesterol-lowering therapy. Although blood cholesterol reduction ameliorated experimental
atherosclerosis in animal models, the two largest human studies with angiographic
observation of arterial lesion change, the NHLBI Type II Coronary Intervention Study and a
study by Cohn et al, had not demonstrated significant treatment effects. Favorable, but
inconclusive, treatment trends were observed in four unrandomized angiographic trials and
one trial too small for evaluation of randomized groups.
The clinical trial was supported by a subproject within a program project grant.
DESIGN NARRATIVE:
CLAS-I was randomized and selectively-blinded. Screening for the trial consisted of five
clinic visits, at which baseline data, including angiographic data, were obtained and a
prerandomization trial of the study drugs was conducted. One hundred eighty-eighty subjects
were randomized to either 30 grams (g) of colestipol hydrochloride plus 3 to 12 g of niacin
daily or to placebo. Both groups received diet intervention. The drug group received less
than 125 milligrams (mg) of cholesterol daily, 22 percent of energy as fat, 10 percent as
polyunsaturated fat, and 4 percent as saturated fat. The placebo group received less than
250 mg of cholesterol per day, 26 percent of energy as fat, 10 percent as polyunsaturated
fat, and 5 percent as saturated fat. The different diet composition for drug and placebo
groups was to enhance the differential in blood cholesterol responses between the two
groups. Study subjects and clinic staff were blinded to the prerandomization study drug
trial lipid responses. Subjects were blinded to treatment assignments. Subjects and staff
were not blinded to on-trial lipid values. The primary endpoint, the global change score,
was change in atherosclerosis observed by angiography of native coronary arteries and aorta
coronary bypass grafts. Evaluation of study end-points was performed by staff and
consultants who were blinded to treatment group assignments, as well as to the temporal
ordering of angiographic data. Subjects were seen monthly for the first six months and then
at two-month intervals. A repeat angiogram was performed at two years. Of the 188 randomized
subjects, 162 completed the study.
On completion of CLAS-I, participants not requiring further bypass surgery were invited to
continue in CLAS-II for an additional two years on their previously assigned treatment.
Blinded study methods were maintained; there was no crossover between treatments. One
hundred thirty-eight subjects continued in CLAS-II; 103 completed a third angiogram before
the CLAS-I outcome was known and CLAS-II terminated. The CLAS-II clinical procedures, lipid,
lipoprotein-cholesterol, and apolipoprotein analyses were the same as in CLAS-I. The CLAS-II
angiographic and file evaluation procedures exactly replicated those in CLAS-I.
The study completion date listed in this record was obtained from the Query/View/Report
(QVR) System.
;
Allocation: Randomized, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|